Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 19/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863665 | 0.87 | RXFP1 (0.80) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL15529379 | 0.78 | RXFP1 (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL15531106 | 0.76 | RXFP1 (1.00) | RXFP1 | |
| SCHEMBL15528722 | 0.76 | RXFP1 (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL4976103 | 0.74 | KDR (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL29356168 | 0.74 | KDR (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL3110637 | 0.73 | KDR (0.66) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL1011471 | 0.73 | RXFP1 (0.80) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL1037818 | 0.70 | RXFP1 (0.75) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL15528871 | 0.70 | RXFP1 (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ | 2006-04-06 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NR2E3, AXL, FLT1 | RXFP1 72/4885ABL1 129/4885EGFR 8/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | RXFP1 87/4885ABL1 152/4885EGFR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.